Pipeline of Women Infertility Market Review Research H2 2015 adds Women Infertility Pipeline 2015 Research to its database, providing in-depth, high quality, transparent and market-driven, expert analysis of disease. This report provides comprehensive information on the therapeutic development for Women Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Women Infertility and special features on late-stage and discontinued projects.

Complete research on pipeline assessment review of Women Infertility with 69 market data tables and 17 figures, spread across 209 pages is available at .

Scope of this research:

·         The report provides a snapshot of the global therapeutic landscape of Women Infertility

·         The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

·         The report reviews key players involved in the therapeutics development for Women Infertility and enlists all their major and minor projects

·         The report summarizes all the dormant and discontinued pipeline projects

·         A review of the Women Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

·         Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

·         A detailed assessment of monotherapy and combination therapy pipeline projects

·         Coverage of the Women Infertility pipeline on the basis of target, MoA, route of administration and molecule type

·         Latest news and deals relating related to pipeline products

Enquire before buying this research @ .

Reasons to buy

·         Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

·         Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

·         Develop strategic initiatives by understanding the focus areas of leading companies

·         Identify and understand important and diverse types of therapeutics under development for Women Infertility

·         Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

·         Devise corrective measures for pipeline projects by understanding Women Infertility pipeline depth and focus of Indication therapeutics

·         Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

·         Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Company Profiles: AbbVie Inc., Addex Therapeutics Ltd, Allergan Plc, AlphaMab Co., Ltd, APAvadis Biotechnologies Srl, ASKA Pharmaceutical Co., Ltd., Astellas Pharma Inc., Bayer AG, BIOCAD, Dong-A Socio Group, Dongkook Pharmaceutical Co., Ltd., ElexoPharm GmbH, EndoCeutics, Inc.,  Enteris BioPharma, Inc., Euroscreen S.A., Evotec AG, Ferring International Center S.A., Finox AG, Forendo Pharma Limited, GlaxoSmithKline Plc, Glycotope GmbH, Kissei Pharmaceutical Co., Ltd., Lipicard Technologies Limited, Merrion Pharmaceuticals Plc, Nippon Shinyaku Co., Ltd., Nora Therapeutics, Inc., ObsEva SA, Orphagen Pharmaceuticals, Inc., Pantec Biosolutions AG, PharmaEssentia Corporation, Philogen S.p.A., Reliance Life Sciences Pvt. Ltd., Repros Therapeutics Inc., SK Chemicals Co., Ltd., Takeda Pharmaceutical Company Limited, TocopheRx, Inc., Trophogen, Inc., ValiRx Plc, Viteava Pharmaceuticals, Inc. and Zydus Cadila Healthcare Limited